Pregnancy-associated plasma protein-A2 and anthropometry, lifestyle, and biochemical factors in a human adult population by Steinbrecher, A. et al.
1SCIEntIfIC RePORTs | 7: 10455  | DOI:10.1038/s41598-017-10629-y
www.nature.com/scientificreports
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Pregnancy-associated plasma protein-A2 (PAPP-A2), a metalloproteinase purportedly related to 
pregnancy, foetal growth and development, has recently been described essential for pre-adult growth. 
Thus, we measured PAPP-A2 in plasma of a non-pregnant population and determined its associations 
with lifestyle, anthropometric or biochemical factors. In this cross-sectional study of 387 participants 
(20–70 years) randomly drawn from registration offices near Berlin, Germany, socio-economic and 
lifestyle factors were assessed by questionnaires, and anthropometric measures and blood samples 
were taken by trained personnel. Blood was analysed for standard clinical parameters. PAPP-A2 
concentration was measured by ELISA. Generalized linear models were used to estimate associations 
with anthropometric and biochemical factors adjusted for age, sex, and weight. Adjusted mean 
PAPP-A2 concentration was slightly higher in women (283 pg/mL) than in men (261 pg/mL, p = 0.05) 
and positively correlated with age (r = 0.17, p = 0.001). PAPP-A2 concentration was inversely associated 
with body mass index (−2.7 pg/mL per kg/m2, p = 0.03) and weight (−1.0 pg/mL per kg, p = 0.01) and 
positively associated with γ-glutamyl transferase (13.6 pg/mL per SD, p = 0.02), aspartate transaminase 
(18.5 pg/mL per SD, p = 0.002) and lactate dehydrogenase (14.9 pg/mL per SD, p = 0.02). Our results 
support that PAPP-A2, beyond its established role in early growth and development is relevant in adult 
metabolisms.
Pregnancy-associated plasma protein-A and -A2 (PAPP-A2) are the only two members of the pappalysin fam-
ily of metalloproteinases1. Substrates of both proteinases are subsets of the insulin-like growth factor binding 
proteins (IGFBPs); PAPP-A2 cleaves and inactivates IGFBP-3 and IGFBP-52. Initial studies suggested that this 
proteinase primarily plays a role during pregnancy, since it is highly expressed in the placenta2, and circulating 
concentrations of PAPP-A2 were found to be increased during gestation3. Cleavage of IGFBPs is believed to cause 
increased insulin-like growth factor (IGF) bioavailability and bioactivity4, which is essential for foetal growth and 
development5.
While the first studies conducted on PAPP-A2 among humans focused on its role in pregnancy3 and in the 
context of maternal preeclampsia6, 7, PAPPA2 expression is neither limited to the placenta nor to the blood during 
pregnancy2. Genetic data have pointed at PAPP-A2 as a determinant of human height8, and it was recently shown 
that the absence of PAPP-A2 in humans causes short stature9. However, to date, details on the role of PAPP-A2 in 
adult general populations remain unknown. The aim of this study was to measure PAPP-A2 in blood plasma of an 
adult human population and to evaluate whether anthropometric or lifestyle factors or biochemical parameters 
are associated with plasma concentrations of PAPP-A2.
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Subjects and Methods
Study population. From September 2011 until December 2012, two cross-sectional pretest studies were 
undertaken at the study center (Max Delbruck Center, Berlin, Germany) to support the implementation of the 
German National Cohort10. For each pretest, a random sample of the general population aged 20–70 years living 
in the vicinity of the study center was drawn from the registration office. The first pretest also allowed the inclu-
sion of participants through convenience sampling (e.g., via e-mail lists). Besides having the principal residence 
in the recruitment area, German language skills and the ability to give informed consent were eligibility criteria. 
All potential participants were invited to take part in a three hour examination at the study center, consisting of 
an interview, medical examinations and a blood draw.
All participants gave written informed consent. The study protocol was approved by the ethics committee of 
Charité University Medicine Berlin and by the local data protection officer. All examinations were carried out in 
accordance with the relevant guidelines and regulations.
Data Assessment. Information on demography, lifestyle factors and medical conditions were collected in 
face-to-face computer-assisted interviews or via self-reported computer-assisted questionnaires. Participants 
indicated sex, date of birth, smoking status (never, former, current), frequency of alcohol consumption during 
the last 12 month (never or occasionally, 1–4 times/month, ≥2 times/week), and if they had ever been diagnosed 
with diabetes, osteoporosis, autoimmune diseases (i.e. systemic lupus erythematosus or Sjögren’s syndrome), 
or inflammatory bowel diseases (i.e. Crohn’s disease or ulcerative colitis) by a physician. Women were asked for 
reproductive details including current pregnancies and menstrual cycles (yes, no, don’t know).
Anthropometric measurements were performed by trained personnel according to standardized procedures. 
Wearing light underwear, participant’s weight in kg and height in cm was recorded on a digital stadiometer 
(SECA 285, SECA, Hamburg, Germany) up to one decimal place. Waist and hip circumferences were measured 
with a tape measure (SECA 201, SECA, Hamburg, Germany) in cm up to one decimal place.
Blood samples were collected in Sarstedt Monovette® tubes (2.6 mL serum-gel/clotting activator, 9 mL EDTA 
plasma, 2.7 mL EDTA plasma) following a standardized venipuncture protocol. Fasting status was not a prereq-
uisite for blood draw.
The serum tubes were turned twice and rested at room temperature for 30–45 minutes before being centri-
fuged at 2000 g for 15 minutes at 15 °C. The EDTA plasma tubes were turned twice and set on a universal rocking 
mixer for a maximum of 5 minutes. The 2.6 mL serum-gel tube and the 2.7 mL EDTA plasma tube were shipped 
within 6 h to a laboratory for clinical diagnostics (Hospital Laborverbund Brandenburg-Berlin) for stand-
ard measurements of creatinine, uric acid, triglycerides, total cholesterol, high-density lipoprotein cholesterol 
(HDL-C), low-density lipoprotein cholesterol (LDL-C) (direct measurement), glycated haemoglobin A1 (HbA1c), 
sodium, potassium, γ-glutamyl transferase (GGT), aspartate transaminase (ASAT), alanine aminotransferase 
(ALAT), and lactate dehydrogenase (LDH), haemoglobin, haematocrit, erythrocytes, and leukocytes. Creatinine 
concentration was used to estimate glomerular filtration rate (eGFR) in mL/minute according to the MDRD 
formula by Levey et al.11. Impaired kidney function was defined as eGFR ≤60 mL/min.
The 9 mL EDTA tube was centrifuged at 2000 g for 15 minutes (15 °C) and the plasma supernatant was ali-
quoted and immediately frozen on dry ice and stored at −80 °C until measurement of PAPP-A2 with the PAPP-A2 
ELISA kit (AL-109, Ansh Labs, TX, USA)3.
Statistical analysis. We excluded participants with missing data in socio-demographic factors (n = 5), 
in anthropometric measurements (n = 1) and in standard laboratory measurements (n = 11). In addition, we 
excluded one female participant with a PAPP-A2 concentration 10-times the standard deviation (SD) over the 
mean. The final sample size for analysis therefore included 387 participants (157 men and 230 women).
Age in years was calculated as the difference between date of study center visit and birth date and categorized 
into age groups (20- < 30, 30- < 40, 40- < 50, 50- < 60, >  = 60 years). Body mass index (BMI) was calculated as 
weight (in kg) divided by height (in m) squared.
We analysed PAPP-A2 concentrations by sex and age. Further, age-, sex-, and pretest-adjusted mean PAPP-A2 
concentrations (and 95% confidence intervals (CI)) were calculated by categories of lifestyle and medical char-
acteristics. Correlation coefficients between PAPP-A2 concentration and age and partial correlation coefficients 
between PAPP-A2 concentration and anthropometric measures adjusting for age, sex and pretest were computed. 
Multivariable linear regression (generalized linear model) was used to evaluate the association between PAPP-A2 
concentrations and anthropometric and biochemical parameters adjusted for age (continuous), pretest, weight 
(continuously) and sex. We calculated the coefficients from these models to reflect the estimated difference in 
PAPP-A2 concentration for a one unit difference in anthropometric as well as for a one standard deviation differ-
ence in the biochemical factors. We repeated the linear regression for men and women separately and calculated 
p-values for differences between sexes. Further, we performed separate analyses for women with menstrual cycles 
and women without.
In sensitivity analysis we repeated the main analyses with prior exclusion of participants with self-reported 
osteoporosis, diabetes, autoimmune diseases, or inflammatory bowel diseases, or impaired kidney function.
Results
The study population comprised 387 participants (157 men, 230 women) with a mean age of 49 years (range, 20 to 
70 years). BMI, smoking and alcohol consumption characteristics varied slightly between the sexes, with a higher 
percentage of men being overweight, obese, current smoker and consuming ≥2 alcoholic drinks/week compared 
to women (data not shown). Of the 230 women, none reported to be currently pregnant.
PAPP-A2 concentrations were determined in plasma samples of all 387 participants with a median of 251 pg/
mL ranging from 26 pg/mL to 831 pg/mL (interquartile range (IQR): 190–330 pg/mL). Graphical displays of 
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PAPP-A2 concentrations can be found in Fig. 1. In unadjusted analyses, PAPP-A2 concentrations tended to be 
higher among women (median, 259 pg/mL; IQR, 199–333 pg/mL) compared to men (242 pg/mL; IQR, 179–
316 pg/mL; Fig. 1b). PAPP-A2 concentrations were also positively correlated with age (Spearman correlation 
coefficient, r = 0.19; p < 0.001; Fig. 1c). This correlation was similar in men (r = 0.23; p < 0.005) and women 
(r = 0.17; p = 0.01). After adjustment for sex and pretest the correlation between PAPP-A2 concentration and age 
was r = 0.17 (p = 0.001).
Age-, sex-, and pretest-adjusted mean PAPP-A2 concentrations (and 95% CI) according to lifestyle and med-
ical characteristics are given in Table 1. Similar to the unadjusted analyses, PAPP-A2 concentrations were higher 
Figure 1. Graphical presentation of plasma PAPP-A2 concentration (n = 387), (a) frequency distribution (%) 
of PAPP-A2 concentration (pg/mL) by sex, (b) boxplot of PAPP-A2 concentration (pg/mL) stratified by sex, (c) 
scatterplot of PAPP-A2 concentration (pg/mL) above age (years).
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in women (283 pg/mL) compared to men (261 pg/mL) when adjusted for age and pretest. Mean PAPP-A2 concen-
tration did not differ significantly by smoking status. Participants who consumed alcohol 1–4x/month tended to 
have lower mean PAPP-A2 concentration than those who did not drink/only at special occasions, or those drink-
ing ≥2x per week (p = 0.04). The proportion of participants with osteoporosis, diabetes, autoimmune diseases, 
inflammatory bowel diseases or impaired kidney function was low. Participants with inflammatory bowel dis-
eases tended to have higher PAPP-A2 concentrations in comparison with participants indicating no such disease.
With respect to the anthropometric parameters, in age-, sex- and pretest-adjusted analyses we found inverse 
correlations coefficients and associations of PAPP-A2 concentrations with BMI (p = 0.03) and weight (p = 0.01) 
(Table 2). When stratified by sex, these inverse associations were slightly stronger in women compared to men, 
although the difference between sexes was not statistically significant (p = 0.83 and p = 0.35, respectively). Height, 
waist and hip circumference were not significantly associated with PAPP-A2 concentrations at the 5%-level.
The mean ( ± SD) concentrations of biochemical parameters as well as the difference in PAPP-A2 concen-
trations for a one standard deviation difference in concentrations of biochemical parameters is presented in 
Table 3. After adjustment for age, sex, weight, and pretest, we found statistically significant positive associations of 
PAPP-A2 concentration with GGT, ASAT and with LDH concentrations, and statistically significant inverse asso-
ciations with haemoglobin concentration, haematocrit and red blood cell count (Table 3). For example, one SD 
higher LDH concentrations were associated with 14.9 pg/mL higher PAPP-A2 concentrations (p = 0.02), whereas 
one SD higher haemoglobin concentrations were associated with 19.2 pg/mL lower PAPP-A2 concentrations 
(p = 0.01). The remaining biomarkers were not significantly associated with PAPP-A2. In sex stratified analysis 
N %
PAPP-A2 conc. (pg/mL)
p-valuebmeana 95% CI
Sex 0.05
 Men 157 40.6 261 (243–280)
 Women 230 59.4 283 (268–299)
Age group 0.03
 < 30 y 58 15.0 241 (211–270)
 30- < 40 y 45 11.6 252 (218–285)
 40- < 50 y 67 17.3 268 (240–295)
 50- < 60 y 122 31.5 277 (256–298)
 ≥ 60 y 95 24.5 298 (275–321)
Smoking statusc 0.34
 never 203 52.5 274 (257–290)
 current 85 22.0 283 (258–308)
 former 98 25.3 259 (236–282)
Alcohol consumptionc 0.04
 never/special occ. 86 22.2 296 (272–321)
 1–4x month 165 42.6 258 (238–277)
 ≥ 2x week 135 34.9 274 (253–294)
Osteoporosisc,d 0.59
 no 371 95.9 272 (258–285)
 yes 14 3.6 288 (229–347)
Diabetesd 0.10
 no 368 95.1 270 (257–283)
 yes 19 4.9 314 (263–364)
Autoimmune diseasesc,d 0.89
 no 376 97.2 272 (259–286)
 yes 9 2.3 267 (194–340)
Inflammatory bowel diseasec,d 0.03
 no 378 97.7 271 (258–284)
 yes 5 1.3 378 (282–475)
Impaired kidney functione 0.45
 no 372 96.1 272 (258–285)
 yes 15 3.9 294 (237–351)
Table 1. Age-, sex- and pretest-adjusted means of PAPP-A2 concentration (pg/mL) over lifestyle and medical 
characteristics. PAPP-A2, pregnancy-associated plasma protein-A2; conc., concentration; CI, confidence 
interval; aadjusted for age (continuously), pretest and sex (where appropriate). bANOVA. cNumbers do not 
add up to 100% because of missings. dInformation on diseases was self-reported by the participants. eImpaired 
kidney function is defined as an estimated glomerular filtration rate ≤ 60 mL/min (calculated from measured 
serum creatinine concentration according to the MDRD formula by Levey et al.11).
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(Table 3), we found that the inverse associations of PAPP-A2 with red blood cells were restricted to women 
(p-value for difference in the associations between men and women, p = 0.04). Thus, in women, one SD higher 
red blood cell count was associated with 36.4 pg/mL lower PAPP-A2 concentrations (p = 0.0002), whereas no 
such difference was found in men (−9.7 pg/mL, p = 0.33). Similarly, the associations between PAPP-A2 concen-
tration and haemoglobin concentration or haematocrit were borderline significant (p-value for difference = 0.05 
and 0.07, respectively) hinting that these associations might be found in women but not in men.
We decided further to stratify the analysis into women who indicated to still have menstrual cycles (n = 113) 
and women who did not (n = 112) (Table 4). Women with menstrual cycles had a mean age of 38 years (IQR: 
27–48 years) and women without of 58 years (IQR: 54–64 years). In these analyses, we found the inverse associa-
tions between PAPP-A2 concentration and haemoglobin concentration, haematocrit or red blood cell count to be 
slightly stronger in women without menstrual cycles compared to women with menstrual cycles; however, tests 
for interaction were not significant.
All (n = 387) Men (n = 157) Women (n = 230)
p for 
difference
Partial 
correlation 
coefficienta
Diff. in PAPP-A2 
conc. (pg/mL)b p-value
Partial 
correlation 
coefficienta
Diff. in PAPP-A2 
conc. (pg/mL)b p-value
Partial 
correlation 
coefficienta
Diff. in PAPP-A2 
conc. (pg/mL)b p-value
Per unit difference in
BMI (kg/m2) −0.11 −2.7 0.03 −0.10 −2.4 0.21 −0.11 −2.7 0.10 0.83
Weight (kg) −0.13 −1.0 0.01 −0.09 −0.6 0.26 −0.15 −1.3 0.02 0.35
Height (cm) −0.06 −1.0 0.24 0.01 0.1 0.95 −0.10 −1.7 0.12 0.30
Hip circumference (cm) −0.08 −1.0 0.12 −0.07 −0.9 0.41 −0.08 −0.9 0.24 0.97
Waist circumference (cm) −0.09 −0.8 0.10 −0.04 −0.4 0.61 −0.11 −1.1 0.10 0.46
Table 2. Multivariable-adjusted correlations and associations between anthropometric parameters and 
PAPP-A2 concentration (pg/mL). PAPP-A2, pregnancy-associated plasma protein-A2; diff., difference; conc., 
concentration; BMI, body mass index. aPartial correlation coefficient between PAPP-A2 concentration and 
anthropometric measures while adjusting for age (continuously), pretest and sex (where appropriate). bSeparate 
linear regression models for each anthropometric parameter adjusted for age (continuously), pretest and sex 
(where appropriate).
Mean ±SD
All (n = 387)a Men (n = 157)b Women (n = 230)b
p for 
difference
Diff in PAPP-A2 
conc. (pg/mL) p-value
Diff in PAPP-A2 
conc. (pg/mL) p-value
Diff in PAPP-A2 
conc. (pg/mL) p-value
Per SD difference
Creatinine 71.42 15.80 µmol/L 3.0 0.66 7.1 0.41 −4.6 0.69 0.35
Uric acid 294.14 84.35 µmol/L 0.5 0.95 −7.0 0.52 8.8 0.42 0.52
Triglycerides 1.69 1.12 mmol/L −1.4 0.82 2.6 0.72 −10.3 0.35 0.23
HDL-C 1.57 0.50 mmol/L 1.2 0.86 8.0 0.53 −2.1 0.78 0.81
LDL-C 3.37 1.00 mmol/L −4.4 0.49 0.0 0.99 −6.7 0.45 0.57
Cholesterol 5.37 1.15 mmol/L −4.8 0.44 2.4 0.80 −9.8 0.26 0.38
HbA1c 5.62 0.45% 1.9 0.76 −1.4 0.87 4.8 0.59 0.89
Potassium 4.17 0.28 mmol/L −1.4 0.81 5.4 0.56 −5.1 0.50 0.39
Sodium 139.46 1.96 mmol/L 8.1 0.15 4.6 0.62 10.4 0.15 0.70
GGT 0.46 0.45 µkat/L 13.6 0.02 16.3 0.04 10.0 0.28 0.52
ASAT 0.39 0.14 µkat/L 18.5 0.002 20.6 0.01 14.9 0.15 0.75
ALAT 0.41 0.25 µkat/L 11.4 0.07 13.6 0.08 4.1 0.74 0.46
LDH 2.67 0.54 µkat/L 14.9 0.02 20.8 0.02 9.4 0.32 0.27
Haemoglobin 8.34 0.72 mmol/L −19.2 0.01 −4.7 0.70 −33.6 0.002 0.05
Haematocrit 0.40 0.03 −17.6 0.01 −5.1 0.63 −30.5 0.002 0.07
Red blood cells 4.47 0.38 Tpt/L −21.5 0.001 −9.7 0.33 −36.4 0.0002 0.04
White blood cells 6.49 1.78 Gpt/L −7.5 0.18 −15.2 0.09 −2.0 0.78 0.33
Table 3. Mean ( ± SD) concentrations of biochemical parameters and multivariable-adjusted associations 
between biochemical parameters and PAPP-A2 concentration (pg/mL). PAPP-A2, pregnancy-associated plasma 
protein-A2; diff., difference; conc., concentration; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-
density lipoprotein cholesterol; HbA1c, glycated haemoglobin A1; GGT, γ-glutamyl transferase; ASAT, aspartate 
transaminase; ALAT, alanine aminotransferase; LDH, lactate dehydrogenase. aSeparate linear regression 
models for each biochemical parameter adjusted for age (continuously), sex, weight and pretest. bSeparate linear 
regression models for each biochemical parameter adjusted for age (continuously), weight and pretest.
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Finally we repeated our main analyses with prior exclusion of participants with osteoporosis, diabetes, auto-
immune diseases, inflammatory bowel diseases, or impaired kidney function (Table 5). Within this study popu-
lation of 330 participants (136 men and 194 women) we found associations between PAPP-A2 concentration and 
anthropometric or laboratory markers not substantially different from the main analysis.
Discussion
In this cross-sectional study we measured plasma PAPP-A2 concentrations in adult men and non-pregnant 
women of a general study population. The PAPP-A2 concentrations tended to be higher in women in comparison 
to men, and positively correlated with age. While smoking status was not associated with PAPP-A2 concentration, 
we found weak associations with body weight, BMI and alcohol consumption. Among biochemical factors, GGT, 
ASAT and LDH concentrations were positively associated with PAPP-A2 concentration. Haemoglobin concen-
tration, haematocrit and red blood cell count were inversely associated with PAPP-A2, although interaction anal-
yses showed that the inverse associations were restricted to women only.
PAPP-A2 is highly expressed during the course of pregnancy, with a potential role in foetal growth and a 
potential prognostic value for evaluating pre-eclampsia3, 6, 7. Here we present the first study measuring PAPP-A2 
concentration in a large population independent of the pregnancy context. In 2013, Kløverpris et al. introduced 
an immunoassay for PAPP-A2 measurement in human serum3. During assay testing, they measured PAPP-A2 
concentration in serum samples of two male and two female participants and reported a mean concentration of 
300–500 pg/mL3, which is in line with our findings using the same immunoassay.
This far, research has pointed to a role of PAPP-A2 in foetal growth and development, since it is highly 
expressed in the placenta during pregnancy and supposed to increase IGF bioavailability by cleavage of binding 
proteins IGFPB-3 and IGFPB-52. Furthermore, members of two families were recently identified, whose homozy-
gous mutations in PAPPA2 (p.D643fs25* and p.Ala1033Val), lead to a complete absence of PAPP-A2 proteolytic 
activity resulting in increased IGF-1 bound to IGFBPs and decreased free IGF-1 concentrations. The affected 
individuals were characterized by progressive growth failure, moderate microcephaly, thin long bones and mildly 
decreased bone density9. In our analysis in an adult population, we did not find an association between height and 
PAPP-A2 plasma concentration. However, it is quite reasonable, that the potential causal relationships between 
PAPP-A2 concentration and growth do not persist into adulthood, when the growth period is over.
With respect to the other anthropometric measures, we found indications for weak inverse associations of 
PAPP-A2 concentration with weight and BMI. From a theoretical perspective, IGF-1 is supposed to be central 
to the regulation of anabolic (growth) processes12; however, the current knowledge of the biological function of 
PAPP-A2 is too scarce to draw inferences. Much more complexity is added since the relationship between BMI 
and IGF-1 levels is presumably inversely U-shaped, while free IGF increases with obesity13. Furthermore, elevated 
serum IGF-1 levels have been found to be associated with reduced risk of osteoporosis14 and diabetes15 on the one 
hand, while they are associated with a higher risk of breast, colorectal, prostate and lung cancer16, 17 on the other. 
Thus, to elucidate the role of PAPP-A2 in an adult population, a next step would be to determine the relationship 
of PAPP-A2 with concentrations of IGF-1, free IGF1 and IGF binding proteins in an adult population.
We had self-reported information on diagnoses of diabetes, osteoporosis, autoimmune diseases and inflam-
matory bowel diseases in this study population. We found higher adjusted mean PAPP-A2 concentrations in 
participants reporting to have inflammatory bowel diseases in comparison to participants without this condition. 
Furthermore the adjusted means PAPP-A2 concentration in participants indicating diabetes was slightly although 
not significantly higher than in participants without diabetes. It should be noted that the self-reported diagnoses 
of diseases in this study were not validated by physicians’ records or medication information. In addition, given 
that our study population was selected from the general population, the number of diseased persons was relatively 
small. Therefore, results for these subgroups need to be interpreted cautiously. Future studies are warranted to 
explore the association of PAPP-A2 concentration with respect to diabetes or inflammatory bowel diseases.
With respect to biochemical parameters, we found a positive association between PAPP-A2 concentration and 
GGT, ASAT and LDH serum concentration. We point out, that in this study population the concentration of all 
three parameters varied within the normal clinical range, which is also true for white blood cell count as a stand-
ard marker for inflammation. Since all three parameters might function as chronic markers of cell damage18–20 
irrespective of an acute inflammatory event, one might speculate, that in the same way as GGT, ASAT or LDH are 
released from cytosol to the circulation upon cell damage, PAPP-A2 is released, thus leading to increased plasma 
concentrations.
All women (n = 230)
Women with menstrual 
cycles  (n = 113)
Women without menstrual 
cycles (n = 112)
p for 
difference
Diff. in PAPP-A2 
conc. (pg/mL) p-value
Diff. in PAPP-A2 
conc. (pg/mL) p-value
Diff. in PAPP-A2 
conc. (pg/mL) p-value
Per SD difference in
Haemoglobin −33.6 0.002 −17.7 0.16 −46.1 0.007 0.27
Haematocrit −30.5 0.002 −15.9 0.18 −38.8 0.009 0.42
Red blood cells −36.4 0.0002 −11.0 0.41 −46.7 0.0007 0.19
Table 4. Multivariable-adjusted associations between distinct biochemical parameters and PAPP-A2 
concentration (in pg/mL) in all women and stratified by women with and without menstrual cyclesa. PAPP-A2, 
pregnancy-associated plasma protein-A2; diff., difference; conc., concentration. aSeparate linear regression 
models for each biochemical parameter adjusted for age (continuously), weight (continuously) and pretest.
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Interestingly, we found an inverse association between PAPP-A2 concentration and concentrations of haemo-
globin, haematocrit and red blood cells, which was restricted to women. Some studies suggest that concentrations 
of haemoglobin may fluctuate according to the menstrual cycle, due to menstrual blood loss21. One may therefore 
speculate that the inverse association with these blood parameters indicates that PAPP-A2 concentrations also 
depend on menstrual cycle. However, when we stratified the analysis into women still having menstrual cycles 
and those who have not we surprisingly found that the inverse association was even stronger among women not 
having menstrual cycles and weaker (and statistically non-significant) among women having menstrual cycles, 
although the difference between both groups of women was statistically not significant.
The strengths of our study include the selection of the study population, which was predominantly drawn 
from the general population through population registries. It should be noted, subjects willing to participate in 
medical studies are likely to be more health conscious than others, and, therefore our study may not be represent-
ative for the general population22. Nevertheless, the wide variability with respect to age, body mass and lifestyle 
characteristics allowed us to demonstrate association between PAPP-A2 concentration and several parameters 
which might be generalizable. The size of our populations seems appropriate to show biological meaningful differ-
ences in PAPP-A2 concentrations over various lifestyle, anthropometric or biochemical parameters and to repeat 
analyses stratified by gender. Data assessment followed standardized procedures and was conducted by trained 
personnel, especially the measurement of anthropometric parameters followed the WHO protocol23 and did not 
rely on self-reports, which are prone to some errors24. Furthermore all clinical laboratory measurements were 
performed in the same laboratory following standardized procedures and within 6 hours from blood drawing. 
However, triglyceride concentration may be affected by fasting status25 and fasting was not a prerequisite in our 
study; thus, the results with respect to triglycerides concentration should be interpreted cautiously. Measurement 
of LDL-C was performed directly, and thus do not depend on fasting status26. In addition, the method used to 
quantify PAPP-A2 concentration has been extensively tested to determine limit of detection, linearity of dilution 
and spike recovery3. However, the cross-sectional design of our study limits causal inferences.
All (n = 330) Men (n = 136) Women (n = 194)
p for 
difference
Diff. in PAPP-A2 
conc. (pg/mL) p-value
Diff. in PAPP-A2 
conc. (pg/mL) p-value
Diff. in PAPP-A2 
conc. (pg/mL) p-value
Per unit difference in
BMI (kg/m2) −2.8 0.04 −1.8 0.43 −3.4 0.05 0.50
Weight (kg) −1.0 0.02 −0.5 0.42 −1.4 0.02 0.26
Height (cm) −0.9 0.29 −0.2 0.89 −1.4 0.21 0.53
Hip 
circumference 
(cm)
−0.9 0.18 −0.3 0.82 −1.1 0.17 0.54
Waist 
circumference 
(cm)
−1.0 0.06 −0.1 0.93 −1.7 0.02 0.15
Per SD difference in
Creatinine −6.7 0.39 0.9 0.94 −13.8 0.22 0.30
Uric acid −3.7 0.65 −5.8 0.64 −0.1 0.99 0.98
Triglycerides −0.6 0.93 2.6 0.74 −8.7 0.46 0.26
HDL-C 2.7 0.69 13.7 0.33 −2.2 0.78 0.59
LDL-C −1.0 0.89 2.3 0.82 −3.6 0.72 0.53
Cholesterol −0.9 0.90 4.6 0.64 −6.3 0.52 0.39
HbA1c −0.8 0.91 −3.4 0.73 1.6 0.87 0.93
Potassium 3.9 0.53 12.0 0.24 −0.1 0.99 0.35
Sodium 8.4 0.16 1.7 0.86 13.4 0.09 0.37
GGT 10.5 0.09 21.0 0.02 −2.1 0.82 0.05
ASAT 19.0 0.003 25.7 0.004 8.9 0.36 0.22
ALAT 10.9 0.11 16.8 0.06 −4.1 0.73 0.12
LDH 16.7 0.01 23.1 0.02 9.3 0.35 0.21
Haemoglobin −19.5 0.02 −1.2 0.93 −36.1 0.001 0.03
Haematocrit −19.4 0.01 −2.0 0.88 −35.3 0.0006 0.03
Red blood cells −20.0 0.006 −8.7 0.42 −35.6 0.0009 0.05
White blood 
cells −12.0 0.04 −18.1 0.06 −7.1 0.36 0.44
Table 5. Multivariable-adjusted associations between anthropometric and biochemical parameters and 
PAPP-A2 concentration (pg/mL) in participants without osteoporosis, diabetes, autoimmune diseases, 
inflammatory bowel diseases, or impaired kidney function (n = 330)a. PAPP-A2, pregnancy-associated plasma 
protein-A2; diff., difference; conc., concentration. aSeparate linear regression models for each anthropometric 
or biochemical parameter adjusted for age (continuously), pretest and where appropriate for sex and weight 
(continuous).
www.nature.com/scientificreports/
8SCIEntIfIC RePORTs | 7: 10455  | DOI:10.1038/s41598-017-10629-y
In conclusion, this study presented PAPP-A2 concentrations measured in a general adult population of men 
and non-pregnant women. PAPP-A2 concentration was measurable in all participants which is a prerequisite 
for all future studies aiming to further elucidate the biological role of PAPP-A2 in adults. We were able to show 
a widespread distribution of PAPP-A2 concentration with variation over age, sex and weight. PAPP-A2 concen-
trations were positively associated with age and serum concentration of GGT, ASAT and LDH and negatively 
associated with weight in all participants and with serum concentration of haemoglobin, haematocrit and red 
blood cell count in women. However, it is important to direct future research to the simultaneous measurement 
of IGF-1 and IGFBPs, since these are the primary targets of the metalloproteinase PAPP-A2.
Data availability. The datasets generated during and/or analysed during the current study are not publicly 
available due to participants’ data protection reasons and the informed consent, which does not foresee public 
depositing; but datasets are accessible from the corresponding author on reasonable request.
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